
Middle East and Africa Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Appl
Description
Middle East and Africa Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (Bakery and Confectionery, Dairy and Frozen Desserts, Beverages, Sauces; Dressings; and Condiments, RTC and RTE Products, Meat; Poultry and Seafood, and Others)
The intravenous immunoglobulin market in the MEA is expected to grow from US$ 497.97 million in 2022 to US$ 711.99 million by 2028. It is estimated to grow at a CAGR of 6.1% from 2022 to 2028.
Rising Prevalence of Immunodeficiency Diseases
Intravenous immunoglobulin (IVIG) is used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. IVIG is a standard therapy to treat most of the primary immunodeficiencies (PID). The rare genetic diseases can be chronic, weakening, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. As per the Rare Diseases Organization, around 200,000 ITP cases are recorded across the region annually. Thus, increasing prevalence of immunodeficiency diseases drives the growth of the intravenous immunoglobulin market.
Market Overview
The Middle East & Africa intravenous immunoglobulin market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East & Africa. Saudi Arabia was this region's largest intravenous immunoglobulin market in 2021. The Middle East & Africa intravenous immunoglobulin market is anticipated to grow at a CAGR of 6.1% during the forecast period; this growth can be attributed to the increasing government support for healthcare and the rising awareness regarding IgRT. The increasing prevalence of GBS and infectious diseases drives the intravenous immunoglobulin market in Saudi Arabia. According to the article, Application of intravenous immunoglobulin (IVIg) to modulate inflammation in critical COVID-19, published in the National Library of Medicine (NLM) in 2021, administration of IVIg within a specific dosage was extremely beneficial toward reducing mortality and perhaps even the length of hospitalization of patients exhibiting severe COVID-19 symptoms.
MEA Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
MEA Intravenous Immunoglobulin Market Segmentation
The MEA intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.
Based on application, the MEA intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022.
Based on distribution channel, the MEA intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022.
Based on end user, the MEA intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022.
Based on country, the market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of MEA. Saudi Arabia dominated the market in 2022.
ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the SAM traction inverter market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the SAM traction inverter market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the traction inverter market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
The intravenous immunoglobulin market in the MEA is expected to grow from US$ 497.97 million in 2022 to US$ 711.99 million by 2028. It is estimated to grow at a CAGR of 6.1% from 2022 to 2028.
Rising Prevalence of Immunodeficiency Diseases
Intravenous immunoglobulin (IVIG) is used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. IVIG is a standard therapy to treat most of the primary immunodeficiencies (PID). The rare genetic diseases can be chronic, weakening, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. As per the Rare Diseases Organization, around 200,000 ITP cases are recorded across the region annually. Thus, increasing prevalence of immunodeficiency diseases drives the growth of the intravenous immunoglobulin market.
Market Overview
The Middle East & Africa intravenous immunoglobulin market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East & Africa. Saudi Arabia was this region's largest intravenous immunoglobulin market in 2021. The Middle East & Africa intravenous immunoglobulin market is anticipated to grow at a CAGR of 6.1% during the forecast period; this growth can be attributed to the increasing government support for healthcare and the rising awareness regarding IgRT. The increasing prevalence of GBS and infectious diseases drives the intravenous immunoglobulin market in Saudi Arabia. According to the article, Application of intravenous immunoglobulin (IVIg) to modulate inflammation in critical COVID-19, published in the National Library of Medicine (NLM) in 2021, administration of IVIg within a specific dosage was extremely beneficial toward reducing mortality and perhaps even the length of hospitalization of patients exhibiting severe COVID-19 symptoms.
MEA Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
MEA Intravenous Immunoglobulin Market Segmentation
The MEA intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.
Based on application, the MEA intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022.
Based on distribution channel, the MEA intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022.
Based on end user, the MEA intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022.
Based on country, the market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of MEA. Saudi Arabia dominated the market in 2022.
ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the SAM traction inverter market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the SAM traction inverter market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the traction inverter market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table of Contents
171 Pages
- 1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 MEA Intravenous Immunoglobulin Market – By Type
- 1.3.2 MEA Intravenous Immunoglobulin Market – By Application
- 1.3.3 MEA Intravenous Immunoglobulin Market – By Distribution Channel
- 1.3.4 MEA Intravenous Immunoglobulin Market – By End User
- 1.3.5 MEA Intravenous Immunoglobulin Market – By Country
- 2. MEA Intravenous Immunoglobulin Market– Key Takeaways
- 3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
- 4. MEA Intravenous Immunoglobulin Market – Market Landscape
- 4.1 Overview
- 4.2 MEA PEST Analysis
- 4.3 Expert Opinion
- 5. MEA Intravenous Immunoglobulin Market – Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Rising Prevalence of Immunodeficiency Diseases
- 5.1.2 Increasing Geriatric Population
- 5.2 Market Restraints
- 5.2.1 Adverse Effects of Immunoglobulin Therapy
- 5.3 Future Trends
- 5.3.1 Strong Pipeline Candidates for IVIG
- 5.4 Impact Analysis
- 6. Intravenous Immunoglobulin Market– MEA Analysis
- 6.1 MEA Intravenous Immunoglobulin Market Revenue Forecast and Analysis
- 7. MEA Intravenous Immunoglobulin Market Revenue and Forecast to 2028– by Type
- 7.1 Overview
- 7.2 MEA Intravenous Immunoglobulin Market, By Type 2022 & 2028 (%)
- 7.3 IgG
- 7.3.1 Overview
- 7.3.2 IgG Revenue and Forecast to 2028 (US$ Million)
- 7.4 IgM
- 7.4.1 Overview
- 7.4.2 IgM - Revenue and Forecast to 2028 (US$ Million)
- 7.5 IgA
- 7.5.1 Overview
- 7.5.2 IgA - Revenue and Forecast to 2028 (US$ Million)
- 7.6 IgE
- 7.6.1 Overview
- 7.6.2 IgE - Revenue and Forecast to 2028 (US$ Million)
- 7.7 IgD
- 7.7.1 Overview
- 7.7.2 IgD - Revenue and Forecast to 2028 (US$ Million)
- 8. MEA Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Application
- 8.1 Overview
- 8.2 MEA Intravenous Immunoglobulin Market, By Application 2022 & 2028 (%)
- 8.3 Hypogammaglobulinemia
- 8.3.1 Overview
- 8.3.2 Hypogammaglobulinemia - Market Revenue and Forecast to 2028 (US$ Million)
- 8.4 Chronic Inflammatory Demyelinating Polyneuropathy
- 8.4.1 Overview
- 8.4.2 Chronic Inflammatory Demyelinating Polyneuropathy - Market Revenue and Forecast to 2028 (US$ Million)
- 8.5 Immunodeficiency Diseases
- 8.5.1 Overview
- 8.5.2 Immunodeficiency Diseases - Market Revenue and Forecast to 2028 (US$ Million)
- 8.6 Myasthenia Gravis
- 8.6.1 Overview
- 8.6.2 Myasthenia Gravis - Market Revenue and Forecast to 2028 (US$ Million)
- 8.7 Multifocal Motor Neuropathy
- 8.7.1 Overview
- 8.7.2 Multifocal Motor Neuropathy - Market Revenue and Forecast to 2028 (US$ Million)
- 8.8 Idiopathic Thrombocytopenic Purpura
- 8.8.1 Overview
- 8.8.2 Idiopathic Thrombocytopenic Purpura - Market Revenue and Forecast to 2028 (US$ Million)
- 8.9 Inflammatory Myopathies
- 8.9.1 Overview
- 8.9.2 Inflammatory Myopathies - Market Revenue and Forecast to 2028 (US$ Million)
- 8.10 Specific Antibody Deficiency
- 8.10.1 Overview
- 8.10.2 Specific Antibody Deficiency - Market Revenue and Forecast to 2028 (US$ Million)
- 8.11 Guillain-Barre Syndrome
- 8.11.1 Overview
- 8.11.2 Guillain-Barre Syndrome - Market Revenue and Forecast to 2028 (US$ Million)
- 8.12 Others
- 8.12.1 Overview
- 8.12.2 Others - Market Revenue and Forecast to 2028 (US$ Million)
- 9. MEA Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Distribution Channel
- 9.1 Overview
- 9.2 MEA Intravenous Immunoglobulin Market, By Distribution Channel 2022 & 2028 (%)
- 9.3 Hospital Pharmacy
- 9.3.1 Overview
- 9.3.2 Hospital Pharmacy - Market Revenue and Forecast to 2028 (US$ Million)
- 9.4 Retail Pharmacy
- 9.4.1 Overview
- 9.4.2 Retail Pharmacy - Market Revenue and Forecast to 2028 (US$ Million)
- 9.5 Others
- 9.5.1 Overview
- 9.5.2 Others - Market Revenue and Forecast to 2028 (US$ Million)
- 10. MEA Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by End User
- 10.1 Overview
- 10.2 MEA Intravenous Immunoglobulin Market, By End User 2022 & 2028 (%)
- 10.3 Hospitals
- 10.3.1 Overview
- 10.3.2 Hospitals - Market Revenue And Forecasts To 2028 (US$ Million)
- 10.4 Specialty Clinics
- 10.4.1 Overview
- 10.4.2 Specialty Clinics - Market Revenue And Forecasts To 2028 (US$ Million)
- 10.5 Others
- 10.5.1 Overview
- 10.5.2 Others - Market Revenue And Forecasts To 2028 (US$ Million)
- 11. MEA Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 – Country Analysis
- 11.1 Overview
- 11.1.1 Middle East & Africa Intravenous Immunoglobulin Market Revenue and Forecast to 2028, by Country (%)
- 11.1.1.1 Saudi Arabia: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
- 11.1.1.1.1 Overview
- 11.1.1.1.2 Saudi Arabia Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
- 11.1.1.1.3 Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
- 11.1.1.1.4 Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Application (US$ Million)
- 11.1.1.1.5 Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Distribution Channel (US$ Million)
- 11.1.1.1.6 Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By End User (US$ Million)
- 11.1.1.2 South Africa: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
- 11.1.1.2.1 Overview
- 11.1.1.2.2 South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
- 11.1.1.2.3 South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
- 11.1.1.2.4 South Africa: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Application (US$ Million)
- 11.1.1.2.5 South Africa: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Distribution Channel (US$ Million)
- 11.1.1.2.6 South Africa: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By End User (US$ Million)
- 11.1.1.3 UAE: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
- 11.1.1.3.1 Overview
- 11.1.1.3.2 UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
- 11.1.1.3.3 UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
- 11.1.1.3.4 UAE: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Application (US$ Million)
- 11.1.1.3.5 UAE: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Distribution Channel (US$ Million)
- 11.1.1.3.6 UAE: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By End User (US$ Million)
- 11.1.1.4 Rest of the Middle East and Africa: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
- 11.1.1.4.1 Overview
- 11.1.1.4.2 Rest of the Middle East and Africa Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
- 11.1.1.4.3 Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
- 11.1.1.4.4 Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Application (US$ Million)
- 11.1.1.4.5 Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Distribution Channel (US$ Million)
- 11.1.1.4.6 Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By End User (US$ Million)
- 12. MEA Intravenous Immunoglobulin Market–Industry Landscape
- 12.1 Overview
- 12.2 Inorganic Growth Strategies
- 12.2.1 Overview
- 12.3 Organic Growth Strategies
- 12.3.1 Overview
- 13. Company Profiles
- 13.1 Takeda Pharmaceutical Company Limited
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 Grifols, S.A.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 Pfizer Inc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 ADMA Biologics, Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 Bio Products Laboratory Ltd.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 Shanghai RAAS
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 Octapharma AG
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 Kedrion S.p.A
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 13.9 CSL Behring (CSL Limited)
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
- 13.10 Prothya Biosolutions B.V.
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
- 14. Appendix
- 14.1 About The Insight Partners
- 14.2 Glossary of Terms in Intravenous Immunoglobulin Market
- LIST OF TABLES
- Table 1. MEA Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
- Table 2. Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
- Table 3. Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Application (US$ Million)
- Table 4. Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Distribution Channel (US$ Million)
- Table 5. Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By End User (US$ Million)
- Table 6. South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
- Table 7. South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Application (US$ Million)
- Table 8. South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Distribution Channel (US$ Million)
- Table 9. South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By End User (US$ Million)
- Table 10. UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
- Table 11. UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Application (US$ Million)
- Table 12. UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Distribution Channel (US$ Million)
- Table 13. UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By End User (US$ Million)
- Table 14. Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
- Table 15. Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Application (US$ Million)
- Table 16. Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Distribution Channel (US$ Million)
- Table 17. Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By End User (US$ Million)
- Table 18. Recent Inorganic Growth Strategies in the Intravenous Immunoglobulin Market
- Table 19. Recent Organic Growth Strategies in the Intravenous Immunoglobulin Market
- Table 20. Glossary of Terms in Intravenous Immunoglobulin Market
- LIST OF FIGURES
- Figure 1. MEA Intravenous Immunoglobulin Market Segmentation
- Figure 2. MEA Intravenous Immunoglobulin Market Segmentation, By Country
- Figure 3. MEA Intravenous Immunoglobulin Market Overview
- Figure 4. MEA Intravenous Immunoglobulin Market, by Type
- Figure 5. MEA Intravenous Immunoglobulin Market, by Country
- Figure 6. Middle East & Africa: PEST Analysis
- Figure 7. Impact Analysis
- Figure 8. MEA Intravenous Immunoglobulin Market– Revenue Forecast and Analysis – 2020 - 2028
- Figure 9. MEA Intravenous Immunoglobulin Market, by Type 2022 & 2028 (%)
- Figure 10. MEA IgG Revenue and Forecasts to 2028 (US$ Million)
- Figure 11. MEA IgM - Revenue and Forecasts to 2028 (US$ Million)
- Figure 12. MEA IgA - Revenue and Forecasts to 2028 (US$ Million)
- Figure 13. MEA IgE - Revenue and Forecasts to 2028 (US$ Million)
- Figure 14. MEA IgD - Revenue and Forecasts to 2028 (US$ Million)
- Figure 15. MEA Intravenous Immunoglobulin Market, by Application 2022 & 2028 (%)
- Figure 16. MEA Hypogammaglobulinemia - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 17. MEA Chronic Inflammatory Demyelinating Polyneuropathy - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 18. MEA Immunodeficiency Diseases - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 19. MEA Myasthenia Gravis - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 20. MEA Multifocal Motor Neuropathy - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 21. MEA Idiopathic Thrombocytopenic Purpura - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 22. MEA Inflammatory Myopathies - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 23. MEA Specific Antibody Deficiency - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 24. MEA Guillain-Barre Syndrome - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 25. MEA Others - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 26. MEA Intravenous Immunoglobulin Market, by Distribution Channel 2022 & 2028 (%)
- Figure 27. MEA Hospital Pharmacy - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 28. MEA Retail Pharmacy - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 29. MEA Others - Market Revenue and Forecasts to 2028 (US$ Million)
- Figure 30. MEA Intravenous Immunoglobulin Market, by End User 2022 & 2028 (%)
- Figure 31. MEA Hospitals - Market Revenue And Forecasts To 2028 (US$ Million)
- Figure 32. MEA Specialty Clinics - Market Revenue And Forecasts To 2028 (US$ Million)
- Figure 33. MEA Others- Market Revenue And Forecasts To 2028 (US$ Million)
- Figure 34. Middle East & Africa Intravenous Immunoglobulin Market Revenue Overview, by Country, 2022 (US$ Million)
- Figure 35. Middle East & Africa Intravenous Immunoglobulin Market Revenue and Forecast to 2028, by Country (%)
- Figure 36. Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
- Figure 37. South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
- Figure 38. UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
- Figure 39. Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.